Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.
- M. Konopleva, R. Contractor, M. Andreeff
- Biology, MedicineCancer Cell
- 1 November 2006
Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression
- E. Spaeth, J. Dembinski, F. Marini
- Biology, MedicinePLoS ONE
- 7 April 2009
Evidence is provided that TAF are derived from mesenchymal stem cells that acquire a TAF phenotype following exposure to or systemic recruitment into adenocarcinoma xenograft models including breast, pancreatic, and ovarian and under long-term tumor conditioning in vitro, MSC express TAF–like proteins.
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
- H. Kantarjian, S. O'brien, E. Freireich
- MedicineJournal of Clinical Oncology
- 1 February 2000
Hyper-CVAD therapy is superior to previous regimens and should be compared with established regimens in adult ALL, and a smaller percentage had more than 5% day 14 blasts and better survival.
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
- M. Keating, S. O'brien, H. Kantarjian
- Medicine, BiologyJournal of Clinical Oncology
- 20 June 2005
FCR produced a high CR rate in previously untreated CLL, and most patients had no detectable disease on flow cytometry at the end of therapy.
Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.
- M. Studeny, F. Marini, R. Champlin, C. Zompetta, I. Fidler, M. Andreeff
- Biology, MedicineCancer Research
- 1 July 2002
It is demonstrated that, for the purpose of anticancer therapy, bone marrow-derived mesenchymal stem cells (MSCs) can produce biological agents locally at tumor sites and that the tumor microenvironment preferentially promotes the engraftment of MSCs as compared with other tissues.
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
- R. Garzon, Shujun Liu, G. Marcucci
- Biology, ChemistryBlood
- 18 June 2009
Novel functional links between miRNAs and aberrant DNA hypermethylation in acute myeloid leukemia and suggest a potentially therapeutic use of synthetic miR-29b oligonucleotides as effective hypomethylating compounds are provided.
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
- S. Giralt, P. Thall, R. Champlin
- MedicineBlood
- 1 February 2001
Fludarabine/melphalan combinations are feasible in older patients with associated comorbidities, and long-term disease control can be achieved with reduced-intensity conditioning in this population, according to multivariate analysis.
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.
- R. Garzon, S. Volinia, C. Croce
- Biology, MedicineBlood
- 15 March 2008
It is concluded that miRNA expression in AML is closely associated with cytogenetics and FLT3-ITD mutations, and a small subset of miRNAs is correlated with survival.
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells
- R. Tibes, Y. Qiu, S. Kornblau
- BiologyMolecular Cancer Therapeutics
- 1 October 2006
RPPA is a highly reliable, reproducible, high-throughput system that allows for the rapid large-scale proteomic analysis of protein expression and phosphorylation state in primary acute myelogenous leukemia cells, cell lines, and in human stem cells.
Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas.
- A. Nakamizo, F. Marini, F. Lang
- Medicine, BiologyCancer Research
- 15 April 2005
It is concluded that hMSCs can integrate into human gliomas after intravascular or local delivery, that this engraftment may be mediated by growth factors, and that this tropism of hMSC for human gl iomas can be exploited to therapeutic advantage.
...
...